Societal costs and benefits of treatment with trastuzumab in patients with early HER2neu-overexpressing breast cancer in Singapore

BMC Cancer

Volumn 11, Issue , 2011, Pages

  de Lima Lopes Jr, Gilberto ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER PATIENT; CARDIOTOXICITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRODUCTIVITY; PROTEIN EXPRESSION; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SINGAPORE; SOCIOECONOMICS; BREAST TUMOR; CANCER STAGING; ECONOMICS; FEMALE; ITALY; METABOLISM; PATHOPHYSIOLOGY; STATISTICAL MODEL; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; ITALY; MODELS, STATISTICAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; SINGAPORE; UNITED STATES;

EID: 79959317313     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-178     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA: A Cancer Journal for Clinicians 2010, 60:277-300.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61:69-90.
3. Singapore Cancer Registry Interim Report Trends in Cancer Incidence in Singapore 2002-2006, National Registry of Diseases Office. Singapore Cancer Registry Interim Report.
4. Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, et al. the Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 2005, 353:1659-1672. 10.1056/NEJMoa052306, 16236737, the Herceptin Adjuvant (HERA) Trial Study Team.
5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
6. Lopes G, Gluck S. Health Economics in the Journal of Clinical Oncology and an Evaluation of the Indirect Costs and Benefits Associated With Adjuvant Trastuzumab. J Clin Oncol 2007, 25(22):3382-3383. 10.1200/JCO.2007.12.3760, 17664490.
7. Liberato NL, Marchetti M, Liberato GB. Cost-effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007, 25:625-633. 10.1200/JCO.2006.06.4220, 17308267.
8. Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu-Positive Breast Cancer. J Clin Oncol 2007, 25:634-641. 10.1200/JCO.2006.06.3081, 17308268.
9. Garrison LP, Lubeck D, Lalla D. Cost effectiveness analysis of Trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007, 110(3):489-498. 10.1002/cncr.22806, 17592827.
10. International Monetary Fund Gross National Income per capita, 2005 2005, Accessed on 10 July 2009, International Monetary Fund., http://www.imf.org
11. European central bank Exchange rates. 2009, Accessed on 10 July 2009, European central bank., http://www.ecb.org
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996, 276:1253-1258. 10.1001/jama.276.15.1253, 8849754.
13. World Bank 2005 GNI per capita 2005, Atlas method and PPP. Accessed on 10 July 2009, World Bank 2005., http://siteresources.worldbank.org/ICPINT/Resources/Atlas_2005.pdf
14. International Monetary Fund 2005, Accessed on 10 July 2009, International Monetary Fund., http://www.imf.org/external/country/SGP/index.htm
15. Monetary authority of Singapore Singapore dollar exchange rate 2009, Accessed on 10 July 2009, Monetary authority of Singapore., http://www.mas.gov.sg
16. Ministry of Health, Singapore Health care financing 2009, Accessed on 10 August 2009, Ministry of Health, Singapore., http://www.moh.gov.sg
17. National Institute for Health and Clinical Excellence Definitions of cost-effectiveness 2009, Accessed on 10 July 2009, National Institute for Health and Clinical Excellence., http://www.nice.org.uk
18. Hillner BE, Smith TJ. Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing. J Clin Oncol 2009, 27:2111-2113. 10.1200/JCO.2008.21.0534, 19332715.
19. Murray CJ, Evans DB, Acharya A, Baltussen RMPM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000, 9:235-251. 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O, 10790702.
20. Centers for medicare and medicaid Centers for Medicare and Medicaid services 2009, Accessed on 10 August 2009, Centers for medicare and medicaid., http://www.cms.hhs.gov/
21. Stiglitz J. Making globalization work 2006, WW Norton, New York, NY.
22. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, . the FinHer Study Investigators Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. N Engl J Med 2006, 354:809-20. 10.1056/NEJMoa053028, 16495393, the FinHer Study Investigators.